News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F) Release: MIV-247 Has Been Selected as a Candidate Drug and Enters Development for the Treatment of Neuropathic Pain



10/10/2013 9:36:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden – Medivir AB (OMX:MVIR) announced that MIV-247 has been selected as a candidate drug (CD) from its cathepsin S inhibitor project for the treatment of neuropathic pain, and is entering non-clinical development.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES